Pre-Treatment Nutritional Status as a Predictor of Clinical Outcomes in Moderate-to-Severe Plaque Psoriasis Patients Undergoing Cyclosporine A Therapy
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Psoriasis patients often have poor nutrition, impacting treatment. Optimizing diet before cyclosporine A (CsA) therapy improves outcomes and psoriasis severity.
Area Of Science
- Dermatology
- Immunology
- Nutritional Science
Background
- Psoriasis is a chronic immune-mediated disease linked to systemic inflammation and metabolic issues.
- Diet significantly influences inflammatory pathways, but its effect on systemic therapy outcomes is not well understood.
Purpose Of The Study
- To investigate the association between baseline nutritional status and therapeutic response to cyclosporine A (CsA) in psoriasis patients.
- To identify specific nutrient inadequacies that may predict treatment outcomes.
Main Methods
- 37 psoriasis patients undergoing CsA therapy were assessed for dietary intake using 24-hour recalls and food frequency questionnaires.
- Psoriasis severity was evaluated using Psoriasis Area and Severity Index (PASI) and Body Surface Area (BSA) at baseline and follow-up.
- Mixed-effects regression models analyzed the relationship between nutrient adequacy and clinical outcomes, adjusting for BMI, age, and sex.
Main Results
- Patients frequently showed inadequate intake of polyunsaturated fatty acids, fiber, vitamin D, folate, magnesium, and zinc, with excess saturated fat and sodium.
- Adequate intake of fiber, EPA+DHA, vitamins A and D, folate, magnesium, and zinc correlated with lower baseline PASI/BSA and improved outcomes.
- Higher BMI, older age, and male sex were associated with poorer treatment response.
Conclusions
- Pre-treatment nutritional deficiencies are prevalent in psoriasis patients and predict a reduced response to CsA therapy.
- Nutritional optimization prior to CsA treatment may enhance efficacy and support disease management.
- Integrating dietary assessments into psoriasis care can be a valuable adjunct to pharmacotherapy.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...